Concomitant chemoradiotherapy followed by adjuvant chemotherapy in parotid gland undifferentiated carcinoma

Undifferentiated carcinoma of the parotid gland is a poor-prognosis lesion. Results in unresectable lesions, treated with radiotherapy alone, are very disappointing. Six patients with T3-4 N0-1 inoperable lesions were treated with conventional radiotherapy (64-70 Gy, 2 Gy per fraction 5 times a week...

Full description

Saved in:
Bibliographic Details
Published in:Tumori 2001-01, Vol.87 (1), p.14-17
Main Authors: Airoldi, M, Gabriele, A M, Gabriele, P, Pedani, F, Marchionatti, S, Succo, G, Beatrice, F, Bumma, C
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Carcinoma - drug therapy
Carcinoma - radiotherapy
Chemotherapy, Adjuvant
Disease-Free Survival
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Parotid Neoplasms - drug therapy
Parotid Neoplasms - radiotherapy
Radiotherapy Dosage
Radiotherapy, Adjuvant
Survival Analysis
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Undifferentiated carcinoma of the parotid gland is a poor-prognosis lesion. Results in unresectable lesions, treated with radiotherapy alone, are very disappointing. Six patients with T3-4 N0-1 inoperable lesions were treated with conventional radiotherapy (64-70 Gy, 2 Gy per fraction 5 times a week) and concomitant cisplatin (100 mg/m2, days 1, 22 and 43). Four weeks after radiotherapy, adjuvant chemotherapy (cisplatin, 80 mg/m2, day 1, + VP16, 100 mg/m2, days 1, 3 and 5, q = 3 weeks, for 3 cycles) was given. A median dose of 66 Gy (range, 64-70 Gy) was delivered, and all patients received 3 courses of cisplatin during radiotherapy. Five of 6 patients received all three chemotherapeutic adjuvant courses. Two months after the end of treatment, 3 CR (50%), 2 PR (33%) and 1 NC (16%) was observed. Median CR and PR duration was 26+ and 10 months, respectively. Median overall survival was 18 months. No severe acute or late toxicity was observed. Concomitant chemoradiotherapy followed by adjuvant chemotherapy in advanced unresectable undifferentiated parotid carcinoma is feasibile and well tolerated. The high percentage of long-lasting CR is encouraging.
ISSN:0300-8916
2038-2529
DOI:10.1177/030089160108700103